1. Home
  2. UROY vs EOLS Comparison

UROY vs EOLS Comparison

Compare UROY & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UROY
  • EOLS
  • Stock Information
  • Founded
  • UROY 2017
  • EOLS 2012
  • Country
  • UROY Canada
  • EOLS United States
  • Employees
  • UROY N/A
  • EOLS N/A
  • Industry
  • UROY
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • UROY
  • EOLS Health Care
  • Exchange
  • UROY Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • UROY 438.3M
  • EOLS 406.9M
  • IPO Year
  • UROY N/A
  • EOLS 2018
  • Fundamental
  • Price
  • UROY $4.03
  • EOLS $6.97
  • Analyst Decision
  • UROY Strong Buy
  • EOLS Strong Buy
  • Analyst Count
  • UROY 1
  • EOLS 4
  • Target Price
  • UROY $4.50
  • EOLS $21.25
  • AVG Volume (30 Days)
  • UROY 5.8M
  • EOLS 862.2K
  • Earning Date
  • UROY 12-11-2025
  • EOLS 11-05-2025
  • Dividend Yield
  • UROY N/A
  • EOLS N/A
  • EPS Growth
  • UROY N/A
  • EOLS N/A
  • EPS
  • UROY N/A
  • EOLS N/A
  • Revenue
  • UROY $35,266,447.00
  • EOLS $277,941,000.00
  • Revenue This Year
  • UROY $195.97
  • EOLS $13.68
  • Revenue Next Year
  • UROY N/A
  • EOLS $27.96
  • P/E Ratio
  • UROY N/A
  • EOLS N/A
  • Revenue Growth
  • UROY 14.29
  • EOLS 17.15
  • 52 Week Low
  • UROY $1.43
  • EOLS $5.71
  • 52 Week High
  • UROY $5.37
  • EOLS $17.44
  • Technical
  • Relative Strength Index (RSI)
  • UROY 50.35
  • EOLS 59.28
  • Support Level
  • UROY $3.69
  • EOLS $6.67
  • Resistance Level
  • UROY $4.20
  • EOLS $6.90
  • Average True Range (ATR)
  • UROY 0.35
  • EOLS 0.27
  • MACD
  • UROY -0.07
  • EOLS 0.10
  • Stochastic Oscillator
  • UROY 19.94
  • EOLS 98.15

About UROY Uranium Royalty Corp.

Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: